EMA (EU)
GUIDANCE FINAL
ICH M13B guideline on bioequivalence for immediaterelease solid oral dosage forms - additional strengths biowaiver - Step 5
Published: 9/21/2026Detected: 9/21/2026
Summary preview
Provides an ICH/EMA framework to justify bioequivalence (BE) waivers for additional strengths of immediate-release solid oral products when BE/efficacy-safety has been shown for at least one strength.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountclinical
manufacturing
quality
safety
labeling
#ICH M13B
#bioequivalence
#biowaiver
#immediate-release
#solid oral dosage forms
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Pharmacovigilance Risk Assessment Committee (PRAC): 23 - 26 November 202611/23/2026
- Seventeenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines11/20/2026
- EMA annual call with General Practitioner Organisations' representatives11/20/2026
- Digitalisation and artificial intelligence in pharmaceutical manufacturing: Quality Innovation Group (QIG) - Follow-up roundtable meeting11/18/2026
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - November 202611/18/2026